SAM Holdings forms strategic review committee amidst continuing net loss

Returns from its proton beam therapy have been slower than expected.

The Singapore Institute of Advanced Medicine Holdings (SAM) has formed a strategic review committee (SRC) in its bid to address the company’s continuous net loss.

The ramp-up in SAM’s business on the proton beam therapy has been slower than expected due to delays in being included on the panels of healthcare providers of insurance companies, low patient flow, and competition.

The lower revenue with higher operating expenses has resulted in the group continuing to record net losses, negative working capital, and negative cash flow from operations.

The SRC, comprising of non-executive directors of the company, will assist the executive management team on various ongoing and new initiatives focused on improving proton beam therapy utilisation and photon radiation therapy facilities.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia